Âé¶ą´«Ă˝É«ÇéƬ

Journal News

Targeting toxins to treat whooping cough

Isabel Casas Emily Ulrich
May 1, 2025

Whooping cough is an infectious respiratory disease caused by the bacteria Bordetella pertussis. According to the U.S. Centers for Disease Control and Prevention, whooping cough cases are rising. While early antibiotic treatment can be effective, most diagnoses do not occur until after this therapeutic window has passed.

Whooping cough bacteria
Whooping cough bacteria

In a recent Journal of Biological Chemistry , Stefanie Lietz from Ulm University, Germany, and an international team explored the human peptidome — the complete collection of peptides in the human body — for pertussis toxin, or PT, inhibitors using peptide libraries, fractionation and mass spectrometry. They identified the liver protein α1-antitrypsin, or α1AT, as a potent PT inhibitor. Additional cell culture and molecular modeling experiments indicated that α1AT likely binds to PT in solution and thus blocks the toxin from making contact with its known host glycoprotein cell surface interaction partner for endocytosis.

Patients with genetic α1AT deficiency receive synthetic α1AT in the clinic. Therefore, α1AT may be able to be repurposed to treat PT-mediated pertussis pathogenesis. Future studies will fill in details about α1AT’s mechanism of action against PT, such as verifying the α1AT residues involved in binding PT.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Isabel Casas

Isabel Casas is the ASBMB’s publications director.

Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.